Evidence map›Paper›PMID 32224310›Full record

Observational studyThe Lancet. Infectious diseases2020

Clinical and virological data of the first cases of COVID-19 in Europe: a case series.

Francois-Xavier Lescure, Lila Bouadma, Duc Nguyen, Marion Parisey, Paul-Henri Wicky, Sylvie Behillil, Alexandre Gaymard, Maude Bouscambert-Duchamp, Flora Donati, Quentin Le Hingrat and 13 more

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 617 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
617citing papers in PubMed, 7 pooled it
29.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04470648 completednot on this map

COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey

TypeobservationalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2020 to 2021Enrolled179ConditionsSARS-COV2 InfectionArmsblood test for SARS-COV2 serology
NCT04610541 phase3unknown statusnot on this map

Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients

TypeinterventionalSponsorUniversity of PecsRan2020 to 2021Enrolled2,000ConditionsSARS-CoV-2 InfectionArmsRemdesivir-HU
3 · Its place in the literature

Who cites it

617 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,189 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Review
  10. Review
  11. Genetic Characteristics ofPathogens (Basel, Switzerland) · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Multidrug resistantCurrent research in microbial sciences · 2025
    Review
  18. Percutaneous tracheostomy in COVID-19 patients: a retrospective cohort study.Sao Paulo medical journal = Revista paulista de medicina · 2025
    Article
  19. Observational
  20. Article

557 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Francois-Xavier LescureDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Lila BouadmaMedical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Duc NguyenDepartment of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux, France; INSERM U1219, University of Bordeaux, Bordeaux, France.
Marion PariseyDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.
Paul-Henri WickyMedical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Sylvie BehillilNational Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France.
Alexandre GaymardNational Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France; Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.
Maude Bouscambert-DuchampNational Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France; Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.
Flora DonatiNational Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France.
Quentin Le HingratDepartment of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Vincent EnoufNational Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France; Mutualized Platform of Microbiology, Pasteur International Bioresources Network, The Institut Pasteur, Paris, France.
Nadhira Houhou-FidouhDepartment of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France.
Martine ValetteNational Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France; Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.
Alexandra MaillesSanté Publique France, Saint Maurice, France.
Jean-Christophe LucetInfection Control Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
France MentreDepartment of Epidemiology, Biostatistics and Clinical Research, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Xavier DuvalCenter for Clinical Investigation, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Diane DescampsDepartment of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Denis MalvyDepartment of Infectious Diseases and Tropical Medicine, University Hospital of Bordeaux, Bordeaux, France; INSERM U1219, University of Bordeaux, Bordeaux, France.
Jean-François TimsitMedical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Bruno LinaNational Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France; Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.
Sylvie van-der-WerfNational Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses, CNRS-UMR 3569, The Institut Pasteur, Paris, France.
Yazdan YazdanpanahDepartment of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France. Electronic address: yazdan.yazdanpanah@aphp.fr.
Université Claude Bernard Lyon 1 · FRCentre National de la Recherche Scientifique · FRUniversité de Bordeaux · FRSanté Publique France · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOn Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020.

methodsIn this case series, we followed five patients admitted to Bichat-Claude Bernard University Hospital (Paris, France) and Pellegrin University Hospital (Bordeaux, France) and diagnosed with COVID-19 by semi-quantitative RT-PCR on nasopharyngeal swabs. We assessed patterns of clinical disease and viral load from different samples (nasopharyngeal and blood, urine, and stool samples), which were obtained once daily for 3 days from hospital admission, and once every 2 or 3 days until patient discharge. All samples were refrigerated and shipped to laboratories in the National Reference Center for Respiratory Viruses (The Institut Pasteur, Paris, and Hospices Civils de Lyon, Lyon, France), where RNA extraction, real-time RT-PCR, and virus isolation and titration procedures were done.

findingsThe patients were three men (aged 31 years, 48 years, and 80 years) and two women (aged 30 years and 46 years), all of Chinese origin, who had travelled to France from China around mid-January, 2020. Three different clinical evolutions are described: (1) two paucisymptomatic women diagnosed within a day of exhibiting symptoms, with high nasopharyngeal titres of SARS-CoV-2 within the first 24 h of the illness onset (5·2 and 7·4 log

interpretationWe illustrated three different clinical and biological types of evolution in five patients infected with SARS-CoV-2 with detailed and comprehensive viral sampling strategy. We believe that these findings will contribute to a better understanding of the natural history of the disease and will contribute to advances in the implementation of more efficient infection control strategies.

fundingREACTing (Research & Action Emerging Infectious Diseases).

Indexed as

AdultAged, 80 and overBetacoronavirusBloodChinaCoronavirus InfectionsCOVID-19FecesFemaleFranceHumansMaleMiddle AgedNasopharynxPandemicsPneumonia, ViralRNA, Viral

Identifiers

PMID32224310
PMCPMC7156120
OpenAlexW3013653866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.